uniQure QURE
NASDAQ QURE
$45.96 +0.28 (+0.61%)
As of: Sep 9, 2026 · 3:59 PM EDT

uniQure (QURE) Other Non-Current Liabilities (2015 - 2026)

uniQure (QURE) posted Other Non-Current Liabilities of $18.1 million for Q2 2026, up 6.37% on a QoQ basis from $17.0 million in Q1 2026, and up 13.7% year-over-year from $15.9 million in Q2 2025.

Analysis

uniQure (QURE) Other Non-Current Liabilities (2015 - 2026) Analysis & Trends

uniQure has reported Other Non-Current Liabilities for 12 years, with the latest figure at $18.1 million in Q2 2026.

  • On a quarterly basis, Other Non-Current Liabilities rose 13.7% year-over-year to $18.1 million in Q2 2026; TTM through Jun 2026 was $18.1 million, a 13.7% increase from a year earlier, with the FY2025 full-year figure at $18.7 million, up 72.52% from the prior year.
  • Other Non-Current Liabilities was $18.1 million for Q2 2026 at uniQure, up from $17.0 million in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $42.2 million in Q1 2024, with the low at $9.3 million in Q4 2022.
  • Average Other Non-Current Liabilities over 5 years is $25.9 million, with a median of $23.9 million recorded in 2022.
  • The sharpest annual moves came in 2022 and 2025: Other Non-Current Liabilities jumped 900.97% in 2022, then tumbled 70.14% in 2025.
  • Over 5 years, Other Non-Current Liabilities stood at $9.3 million in 2022, then soared by 58.51% to $14.8 million in 2023, then dropped by 26.6% to $10.9 million in 2024, then jumped by 72.52% to $18.7 million in 2025, then decreased by 3.33% to $18.1 million in 2026.
  • The last three Other Non-Current Liabilities figures came in at $18.1 million (Q2 2026), $17.0 million (Q1 2026), and $18.7 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Krystal Biotech 10.27 Bn 9.43 Bn 112.79 Mn
2 CRISPR Therapeutics AG 5.17 Bn 5.17 Bn -
3 Iovance Biotherapeutics 3.79 Bn 3.49 Bn 55.72 Mn
4 Legend Biotech 3.68 Bn 2.71 Bn 251.50 Mn
5 uniQure 3.05 Bn 3.05 Bn 5.49 Mn
6 Beam Therapeutics 2.65 Bn 2.65 Bn -
7 Precigen 2.44 Bn 2.44 Bn 52.17 Mn
8 Sarepta Therapeutics 2.33 Bn 1.53 Bn 251.87 Mn
9 Vericel 1.99 Bn 1.83 Bn 56.40 Mn
10 Taysha Gene Therapies 1.97 Bn 1.97 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 18.11 Mn
Mar 31, 2026 17.03 Mn
Dec 31, 2025 18.74 Mn
Sep 30, 2025 17.75 Mn
Jun 30, 2025 15.93 Mn
Mar 31, 2025 12.60 Mn
Dec 31, 2024 10.86 Mn
Sep 30, 2024 41.40 Mn
Jun 30, 2024 40.10 Mn
Mar 31, 2024 42.20 Mn
Dec 31, 2023 14.80 Mn
Sep 30, 2023 40.70 Mn
Jun 30, 2023 37.20 Mn
Mar 31, 2023 36.90 Mn
Dec 31, 2022 9.33 Mn
Sep 30, 2022 32.70 Mn
Jun 30, 2022 29.10 Mn
Mar 31, 2022 31.10 Mn
Dec 31, 2021 29.54 Mn
Sep 30, 2021 23.78 Mn